Basket | Login | Register

 
 
 
 

EPAD releases its first wave of data

Monday 18 November 2019

The European Prevention of Alzheimer’s Dementia (EPAD), a major Europe-wide initiative aiming to improve the understanding of the early stages of Alzheimer’s disease, has announced the release of its first wave of data including the baseline data from the first 500 research participants (V500.0). The project is one of the world’s leading dementia prevention studies involving 39 organisations across multiple sectors. It offers a unique platform for testing and developing preventative treatments for Alzheimer’s dementia. This represents the first formal public data release from the EPAD project for use by academic researchers and institutions worldwide, which consists of data from research participants over 50 years old who do not have a diagnosis of dementia. The domains of assessment are cognition, neuroimaging, fluid biomarkers, genetics, lifestyle, clinical and psychiatric assessment, neuropsychiatric symptoms, function and basic demography.

Data are provided via secure online tools in order to facilitate collaboration between people and teams with similar research aims. Academic researchers and institutions from all over the world are invited to begin the application process. To access the data, you will need to make an online request by following the link at www.ep-ad.org/erap where you will find a variety of resources to support your research. In the chosen nomenclature (V500.0): V=version, ‘500’ is the number of sequentially recruited research participants in each dataset and ‘.0’ refers to the study visit the dataset includes (visit 0 refers to the baseline data). Each data set will have a digital object identifier (DOI)  to reference the source of the data in subsequent publication (V500.0: doi:10.34688/epadlcs_v500.0_19.05.10). The EPAD project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

Options